P4HA2: A link between tumor-intrinsic hypoxia, partial EMT and collective migration

Vaishali Aggarwal\textsuperscript{a}, Sarthak Sahoo\textsuperscript{b}, Vera S. Donnenberg\textsuperscript{a,c,d,e}, Priyanka Chakraborty\textsuperscript{b}, Mohit Kumar Jolly\textsuperscript{b}, Shilpa Sant\textsuperscript{a,c,d,e,f,*}

\textsuperscript{a}Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
\textsuperscript{b}Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India
\textsuperscript{c}Department of Cardiothoracic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
\textsuperscript{d}McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA
\textsuperscript{e}UPMC-Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
\textsuperscript{f}Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA

Abstract

Epithelial-to-mesenchymal transition (EMT), a well-established phenomenon studied across pan-cancer types, has long been known to be a major player in driving tumor invasion and metastasis. Recent studies have highlighted the importance of partial EMT phenotypes in metastasis. Initially thought as a transitional state between epithelial and mesenchymal phenotypic states, partial EMT state is now widely recognized as a key driver of intra-tumoral heterogeneity and phenotypic plasticity, further accelerating tumor metastasis and therapeutic resistance. However, how tumor microenvironment regulates partial EMT phenotypes remains unclear. We have developed unique size-controlled three-dimensional microtumor models that recapitulate tumor-intrinsic hypoxia and the emergence of collectively migrating cells. In this study, we further interrogate these microtumor models to understand how tumor-intrinsic hypoxia regulates partial EMT and collective migration in hypoxic large microtumors fabricated from T47D breast cancer cells.

We compared global gene expression profiles of hypoxic, migratory microtumors to that of non-hypoxic, non-migratory microtumors at early and late time-points. Using our microtumor models, we identified unique gene signatures for tumor-intrinsic hypoxia (early versus late), partial EMT and migration (pre-migratory versus migratory phenotype). Through differential gene expression analysis between the microtumor models with an overlap of hypoxia, partial EMT and migration...
signatures, we identified prolyl 4-hydroxylase subunit 2 (P4HA2), a hypoxia responsive gene, as a central regulator common to hypoxia, partial EMT and collective migration. Further, the inhibition of P4HA2 significantly blocked collective migration in hypoxic microtumors. Thus, using the integrated computational-experimental analysis, we identify the key role of P4HA2 in tumor-intrinsic hypoxia-driven partial EMT and collective migration.

Keywords
P4HA2; Tumor-intrinsic hypoxia; Partial EMT; Collective migration; 3D microtumor models; Tumor microenvironment

1. Introduction

Epithelial-to-mesenchymal transition (EMT) during which epithelial cells (E) lose their cell-cell adhesion properties and transition to a mesenchymal state (M), has long been known to drive tumor invasion and metastasis [1-3]. Historically, EMT was thought to have terminal E and M states and earlier studies focused on underlying mechanisms driving EMT [4,5]. Emerging evidence suggests the existence of partial EMT phenotype, a transitional state between the E and M states, wherein the cells retain the epithelial phenotype with gain of mesenchymal phenotype [1,6]. Currently, partial EMT phenotype is characterized by co-expression of epithelial (ECAD, ZO-1) and mesenchymal markers (VIM, SNAI1, β-catenin, ZEB1, FN1, MMP1, ZEB2, NCAD) [7]. The partial EMT phenotypes contribute to tumor heterogeneity, cell cycle regulation, collective migration, metastasis and therapeutic resistance [7]. It is suggested that the E, M and partial EMT subsets of malignant cells are present concurrently during tumor progression driving the intra-tumoral heterogeneity [8,9]. However, the molecular mechanisms that drive partial EMT states still remain understudied.

It is widely accepted that the tumor microenvironment (TME) plays a critical role in tumor progression [10]. TME is shaped by tumor-intrinsic factors (e.g., hypoxia, acidic microenvironment) and tumor-extrinsic factors (extracellular matrix and stromal related factors) [10]. TME consists of heterogeneous cellular composition including malignant cells, endothelial cells, stromal cells, fibroblasts, immune cells and extracellular matrix [10,11]. Of these, tumor-intrinsic hypoxia has been suggested to drive and stabilize partial EMT [8,10,12]. In oesophageal squamous cell carcinoma, malignant cells overexpressed hypoxia inducible factor 1 alpha (HIF1α) and exhibited partial EMT phenotype characterized by co-expression of E-cadherin (E-CAD) and vimentin (VIM) [13]. Acidic microenvironment also contributed to partial EMT in MCF-7 cells, which co-expressed epithelial (ZO-1 and E-CAD) and mesenchymal (VIM, SNAI1 and β-catenin) markers [14]. In addition to tumor-intrinsic factors, tumor-extrinsic factors such as extracellular matrix (fibrinogen or collagen matrix) [15,16], cancer-associated fibroblasts and stromal cells [17,18] and tumor associated macrophages [19,20] have all shown to drive and sustain partial EMT phenotypes. These studies support the collective role of TME in inducing partial EMT tumor states.

To investigate mechanisms by which tumor-intrinsic hypoxia drives partial EMT phenotype, it is imperative to have experimental model systems, which can successfully recapitulate inherent tumor-intrinsic hypoxic microenvironment. Majority of published studies utilize
exposure of 2D cell monolayers or three-dimensional (3D) spheroids to hypoxic chambers, where all cells in 2D monolayers or even outer cells in 3D spheroids are exposed to constant hypoxia, in contrast to the dynamic, spatial oxygen gradients that are observed in vivo [10]. Our lab has engineered a unique 3D microtumor models, which recapitulate tumor-intrinsic hypoxic microenvironment, solely driven by the size of microtumors without any genetic manipulation or any artificial culture conditions [12,21-23]. A major advantage of microtumor models is the ease and reproducibility of generation of both non-hypoxic, non-migratory microtumors (150 μm, control) as well as hypoxic, migratory microtumors (600 μm) in vitro. We have shown that the migratory phenotype is easily induced in large hypoxic microtumors made of parent non-migratory T47D cells without any external stimulus [21-23]. We have also observed the presence of heterogenous tumor states i.e., E, M and E/M (partial EMT) [23]. Specifically, we have shown that the large hypoxic microtumors gain the expression of mesenchymal marker (VIM) between day 3–6 while maintaining epithelial marker (E-CAD) expression, supporting the acquisition of partial EMT phenotype [23]. Subsequent studies highlighted the co-localization of E-CAD+ VIM+ or CD90*CD44*CTK+ (partial EMT) tumor cells at the leading edge of the migratory front, further solidifying the role of partial EMT in driving collective migration [23,24].

The current study delineates how tumor-intrinsic hypoxia drives partial EMT and collective migration. To investigate the potential mechanisms underlying tumor-intrinsic hypoxia-driven partial EMT phenotype, we compared global gene expression profiles obtained from microarray platform of large hypoxic microtumors on early (day 1, 600/D1) and late time-points (day 6, 600/D6) with that of non-hypoxic small microtumors (150/D6). We identified enrichment of hypoxia, partial EMT and migration gene signatures early on day 1 (600/D1) and at later time point (600/D6) in large microtumors. We identified P4HA2, a hypoxia-responsive gene as a central regulator that showed overlap between hypoxia, partial EMT and migration gene signatures. Further, inhibition of P4HA significantly abrogated migration in large microtumors supporting its role in partial EMT and collective migration.

2. Materials and methods

2.1. Cell culture

T47D cell line was purchased from American type culture collection (ATCC). Characterization and authentication of T47D cells was done at the University of Arizona Genomic Core facility using PowerPlex16HS PCR kit as previously described [22,23]. All cell culture supplies and media were procured from Corning® and Mediatech®, respectively, unless otherwise specified. T47D cells were passaged and maintained in T75 flask in Dulbecco’s modified Eagle medium (DMEM) complete growth media (MT10013CV, Corning®, USA) supplemented with 10% fetal bovine serum (FBS) (S11250, Atlanta Biologicals, USA) and 1% penicillin-streptomycin (300-002-CI, Corning®, USA) in a humidified incubator with 5% CO2 at 37 °C. Cells were maintained at 40–60% confluency before seeding into size-controlled hydrogel microwell devices.
2.2. Generation of size-controlled microtumors

The size-controlled T47D microtumors with diameters 100–150 μm (‘small’ microtumors) and 450–600 μm (‘large’ microtumors) were microfabricated using non-adhesive polyethylene glycol (PEG) hydrogel microwell devices as previously described [12,21-23]. Briefly, uniform size 150 μm and 600 μm hydrogel microwell devices (1 × 1 cm²) were fabricated using polydimethyl siloxane (PDMS) stamps containing posts with 1:1 aspect ratio of height: diameter. Polyethylene glycol dimethacrylate (PEGDMA, 1000Da, Polysciences Inc., USA) solution (20% w/v) with 1% w/v photoinitiator (Irgacure-1959, Ciba AG CH-4002, Switzerland) was photo-crosslinked under the PDMS stamps to form size-controlled hydrogel microwells using OmniCure S2000 curing station (200W Lamp, 5W/cm², EXFO, Canada). The fabricated hydrogel microwell devices were sterilized in 70% ethanol under UV light in laminar hood for 1h. Post-sterilization, devices were washed thrice with Dulbecco’s phosphate buffered saline (DPBS) without calcium and magnesium (#21-031-CV, Corning™, USA). Subsequently, T47D cells (1.0×10⁶ T47D cells/50μL/device) were seeded on to 1 × 1 cm² hydrogel microwell devices. Excess cells remaining on top of the gels were washed slowly with DPBS. These cell-seeded microwell devices were then cultured in a humidified incubator with 5% CO₂ at 37 °C for six days with replacement of 50% media every day.

To study how tumor-intrinsic hypoxia drives partial EMT phenotype, large 600 μm microtumors were cultured over 6-day period. The small non-hypoxic and non-migratory 150 μm microtumors [22,23] served as controls.

2.3. Bioinformatic analysis of gene expression profiling data

To investigate the role of tumor-intrinsic hypoxia in driving phenotypic plasticity and collective migration, we have performed microarray analysis of 150/D6, 600/D1 and 600/D6 microtumors [25]. In the current study, we analyzed microarray data deposited in the Gene Expression Omnibus database at the National Center for Biotechnology Information (GSE166211) [25] to establish the link between hypoxia, partial EMT and tissue migration by comparing 600/D1 versus 150/D6 and 600/D6 versus 150/D6 comparison groups.

2.3.1. Identification of differentially expressed genes—Microarray data deposited in the Gene Expression Omnibus database at the National Center for Biotechnology Information (GSE166211) [25] was used for the analysis reported in this study. The microarray analysis for identification of differentially expressed genes in 600/D1 versus 150/D6 as well as 600/D6 versus 150/D6 was carried out as described previously [25]. The statistical analysis on each comparison was performed using Transcriptome Analysis Console (TAC 4.0, ThermoFisher Scientific, USA) using one-way ANOVA. A cut-off p-value of 0.01 was used for hierarchical clustering. Differentially expressed genes were considered significant using p-value ≤0.05, false discovery rate (FDR) ≤0.05, and fold change ± 2.

2.3.2. Statistical enrichment of hypoxia, partial EMT and tissue migration signatures—The gene ontology enrichment of hallmark hypoxia in 600/D1 versus 150/D6 and 600/D6 versus 150/D6 groups was carried out using the pipeline as described in
our previous work [25]. We used partial EMT gene signatures previously identified for head and neck cancer [26] as a reference gene signature set to assess the partial EMT signatures in 600/D1 and 600/D6 microtumors, Gene ontology database for GO: Tissue migration (GO:00090130) [27,28] was used to assess the tissue migratory signatures of the microtumors.

2.3.3. ssGSEA scoring of biological pathways—Hallmark signatures from MsigDB were used to quantify the activity of different biological pathways using the ssGSEA for scoring and quantification of the same [29]. The ssGSEA function [30] in the python package gseapy (https://github.com/zqfang/gseapy) was used for scoring of the biological pathways.

2.4. Multicolor flow cytometry staining

Small and large microtumors were cultured as described under section 2.2. At end of day 1, 3, and 6 of the culture, the microtumors were collected, washed with DBPS and disaggregated by incubating in Trypsin-EDTA for 5–10 min. For flow cytometry, three devices of 150 μm microtumors and 1 device of 600 μm microtumors were pooled to obtain required number of cells for each replicate and 3 such biological replicates for each group (150/D1, 150/D3, 150/D6, 600/D1, 600/D3, 600/D6) were used. The disaggregated cells were resuspended in PBS and processed for flow cytometric staining. Non-specific binding of fluorochrome-conjugated antibodies was minimized by pre-incubating pelleted cell suspensions for 5 min with neat decomplemented (56 °C, 30 min) mouse serum (5 μL) [31]. Prior to intracellular cytokeratin or intracellular E-Cadherin staining, cells were stained for surface E-Cadherin (Biologend, Cat. No. 147315) and fixed with 2% methanol-free formaldehyde (Polysciences, Warrington, PA). Cells were then permeabilized with 0.1% saponin (Beckman Coulter) in DPBS with 0.5% human serum albumin (10 min at room temperature). The permeabilized cell pellets were incubated with 5 μL of neat mouse serum for 5 min, centrifuged and decanted. The cell pellet was disaggregated and incubated with 2 μL of anti-pan cytokeratin-FITC (Beckman Coulter, Cat. No. IM2356U, Clone J1B3). A separate tube containing cells unstained for surface E-Cadherin was incubated after permeabilization with E-Cadherin antibody- (R&D Cat. No. FAB18381P, clone DECMA-1, ECD fluorochrome) to determine total (surface and intracellular) E-Cadherin expression. Finally, cells were resuspended to a concentration of 5 × 10⁶ cells/mL and DAPI (Invitrogen Cat. No. D1306) was added to the cells at a concentration of 10 μg/mL. Cells were acquired on Fortessa SORP flow cytometer (BD Biosciences, San Diego, CA). The instrument was calibrated using CS and T beads (BD Biosciences, Cat. No. 650621), and PMT voltages were adjusted to predetermined target channels using the seventh peak of 8-peak Rainbow Calibration Particles (Spherotech, Lake Forest, IL, Cat. No. RCP-30-SA) as a reference point. FITC (BD Biosciences, Cat. No. 349502 for cytokeratin expression) and single stained BD CompBeads anti-mouse IgG (BD Biosciences Cat. No. 51-90-9001229, for E-Cadherin-CF594 clone DECMA1 expression), and unstained cells (DAPI only) were used as spectral compensation standards [32].
2.5. Analysis of FCS files from flow cytometry

For each sample, data were exported into FCS files and organized by experiment into playlists using VenturiOne software (Applied Cytometry Systems, Dinnington, UK, V7.3). The gate for marker positive events was determined such that all negative controls (isotypes) represented less than 1% of clean events. Analytical data (event count, percent positive, MFI) were exported to CSV files and imported into Excel, where they were associated with sample ID and reagent.

2.6. The Cancer Genome Atlas (TCGA) analysis

We analyzed The Cancer Genome Atlas (TCGA) cohort of breast cancer patients in a subtype specific manner (Luminal A, Luminal B and Basal subtypes) to establish correlation of P4HA2 with epithelial and mesenchymal signatures. We scored each patient sample belonging to a given subtype separately by calculating the epithelial and mesenchymal scores through ssGSEA on the corresponding epithelial or mesenchymal gene lists as provided in the study by Tan et al. [33].

2.7. Treatment of microtumors with prolyl 4-hydroxylase (P4HA) inhibitor

To investigate the role of hypoxia-induced partial EMT on collective migration in large microtumors, we studied the effect of P4HA2 inhibition, a common hypoxia and partial EMT marker identified through our bioinformatic analysis. P4HA2 was inhibited by using 20 μmol/L 1,4-dihydiOphenonthrolin-4-one-3-carboxylic acid (1,4-DPCA) (SC-200758, Santa Cruz, USA). 1,4-DPCA, is a selective inhibitor of prolyl 4-hydroxylase, which potentially targets HIF-1α upon hydroxylation of proline residue. Large 600 μm microtumors were treated with 1,4-DPCA (20 μM) from day 1 over six-day period with replenishment with every change of media. To evaluate the effect of P4HA inhibition (P4HA2i) on collective migration of microtumors, number of migrating and non-migrating microtumors were counted on day 3 and day 6 (control versus treated microtumor devices). In addition, the control versus treated microtumors were also imaged at 4x and 10x magnification (Zeiss Primo-vert) on day 3 and day 6, and distance of migration (d) was calculated as described previously [23] for evaluating migration kinetics. Post-treatment, microtumors were collected on day 3 and day 6, respectively from control (untreated) and P4HA2i-treated devices for mRNA isolation [23,34].

2.8. Quantitative real time-polymerase chain reaction (qRT-PCR)

To validate the data obtained from microarray experiment, we validated the expression changes using qRT-PCR (QuantStudio 3, Applied Biosystems, USA). For each experiment, microtumors cultured in 1 x 1 cm² devices were harvested from PEG hydrogel devices (at least two devices for 600 μm microtumors and four devices for 150 μm microtumors) and stored in −80 °C in Trizol. RNA was isolated using GeneJET RNA purification kit (#K0732, Thermo Scientific, USA) as per manufacturer’s protocol. DNase I (#EN0521, ThermoScientific, USA) treatment was used to remove genomic DNA from the RNA samples as per manufacturer’s protocol in thermocycler (T100™, Bio-Rad Laboratories, Inc., USA). RNA concentration was quantitated using Nanodrop (#840274200™, Thermo Scientific, USA) and RNA quality was determined by absorbance ratio at 260/280 nm.
Primers for GAPDH (housekeeping gene), P4HA1 and P4HA2, were procured from KiCq-Start™ primers (H_GAPDH3_3, H_P4HA2_1 and H_P4HA2_2, Sigma-Aldrich, USA).

mRNA expression levels of above-mentioned genes were estimated using iTaq™ Universal SYBR® Green One-step qRT-PCR kit (#1725151, Bio-Rad Laboratories Inc., USA) per manufacturer’s protocol. Each reaction was run in triplicates \( (n = 3) \) with no template control (NTC) and no reverse-transcriptase control (RTC). The complete experiment was repeated in triplicates \( (n = 3) \). Relative fold change expression for individual genes was calculated using \( 2^{-\Delta\Delta Ct} \) method \([35]\) and analyzed for fold change expression with respective 600/D6 untreated samples as controls.

2.9. Statistical analysis

Statistical analysis was done using GraphPad Prism (v9.0). Descriptive statistics and statistical comparisons (Student’s t-test, 2-tailed) were performed, and data are represented as mean ± SEM (standard error of mean) from three replicates. Unpaired \( t \)-test was used to compare two groups and \( p \)-value less than 0.05 was considered significant. P-values were Bonferroni-corrected for multiple comparisons.

3. Results

3.1. Tumor-intrinsic hypoxia is enriched in large microtumors compared to small microtumors

To understand the transcriptomic differences between 150/D6, 600/D1 and 600/D6 microtumors, we performed Principal Component Analysis (PCA) on the gene expression matrices containing three biological replicates for each of the three microtumor models. Upon plotting the samples on a two-dimensional PCA space, we found that \(~56\%\) of the variance was explained by the first two PCA components (Fig. 1A). Furthermore, we found that the replicates clustered together on the PCA space with the inter-biological sample distances larger than the distances between replicates for a given biological sample. While 600/D6 microtumors varied from 150/D6 microtumors along the PCA-1 axis, the 600/D1 varied along both PCA-1 and PCA-2 with respect to either 150/D6 or 600/D6 samples.

This difference indicates that some biological processes vary specifically in the 600/D1 and not in the 600/D6 samples, with 150/D6 samples as a control group. To investigate the biological processes that contribute to the variances in these biological samples, we calculated the ssGSEA scores for hallmark pathways for all the three microtumor models. Upon doing a differential analysis of scores between the pairs of microtumor groups 600/D1 versus 150/D6 and 600/D6 versus 150/D6 (Fig. 1B), we found that Hallmark Hypoxia was consistently upregulated in both these comparison sets, along with TNFa signaling, EMT, p53 signaling and unfolded protein response, although to varying degrees. This mapping shows that tumor-intrinsic hypoxia is upregulated as early as day 1 (600/D1 microtumors) and may contribute to initiate the migratory phenotype in these microtumors. To assess the extent of enrichment of hypoxia signature, we calculated the ssGSEA scores for the Hallmark Hypoxia and found that the hypoxia signature was significantly higher in the 600/D1 and 600/D6 compared to 150/D6 microtumors (Fig. 1C).
To obtain a comprehensive list of hypoxia gene signatures for large hypoxic microtumors (600/D1 and 600/D6) compared to small non-hypoxic microtumors (150/D6), we evaluated the overlap between Hallmark Hypoxia in 600/D1 versus 150/D6 and 600/D6 versus 150/D6 comparison groups (Fig. 1D). The gene signatures from Hallmark Hypoxia were collated to generate comprehensive hypoxia gene signature sets for 600/D1 versus 150/D6 (hereafter referred as “early tumor-intrinsic hypoxia gene signature”) and 600/D6 versus 150/D6 (hereafter referred to as “late tumor-intrinsic hypoxia gene signature”). A total of 53 genes were enriched in 600/D1 versus 150/D6 resulting in early tumor-intrinsic hypoxia gene signature while late tumor-intrinsic hypoxia gene signature was enriched with 55 genes in 600/D6 versus 150/D6 (Fig. 1D (i)). The Venn diagram-based comparative analysis identified 13 genes differentially expressed only in 600/D1 and 15 genes expressed only in 600/D6 (Fig. 1D (i)). We also found 40 genes common to both ‘early’ and ‘late’ tumor-intrinsic hypoxia gene signatures that are differentially expressed as early as day 1 (Fig. 1D (ii)). Of these 40 common genes, 37 genes were upregulated, and three genes were downregulated. Of the 13 genes differentially expressed only in 600/D1 (Fig. 1D (iii)), S100A4, GYS1, ALDOC, FAM162A and CCNG2 were most upregulated while MT2A, TIRAP and EXT1 were top downregulated genes (in descending order of expression). In the ‘late tumor-intrinsic hypoxia’ signature of 600/D6 microtumors, PLIN2 was the most upregulated gene followed by JUN, KLF7, PRKCA and IER3 while SLC25A1, SDC2, NDST1, CASP6 and TPBG were top five downregulated genes (in descending order of expression) (Fig. 1D (iv)). Taken together, gene expression analysis of large microtumor models (600/D1, 600/D6) with tumor size-induced natural hypoxia on day 1 and day 6 compared to non-hypoxic 150/D6 microtumors contributed ‘early’ and ‘late’ tumor-intrinsic hypoxia gene signatures.

3.2. Large microtumors exhibit enrichment of partial EMT signature in comparison to small microtumors

Our earlier work has demonstrated that the large 600 μm microtumors with tumor-intrinsic hypoxia gain mesenchymal marker (VIM) without loss of epithelial marker (E-CAD), suggesting acquisition of partial EMT phenotype [23]. Based on these initial findings, we further investigated partial EMT signatures enriched by tumor-intrinsic hypoxia in large 600 μm microtumors on day 1 and day 6.

First, we assessed changes in the epithelial and mesenchymal characteristics of 600/D1 and 600/D6 microtumors compared to control 150/D6 tumors. Specifically, we calculated the ssGSEA scores of epithelial genes as reported by Tan et al. [33] and observed that there was a robust decline in the epithelial nature in 600/D1 and 600/D6 compared to 150/D6 tumors (Fig. 2A). Using the mesenchymal signatures from the same study [33], we found that the mesenchymal signature was upregulated significantly in 600/D6, but not in 600/D1 microtumors (Fig. 2B). This could indicate that the 600/D1 microtumors are more likely to be towards epithelial spectrum of partial EMT phenotype while the 600/D6 microtumors are more likely to be towards mesenchymal spectrum of partial EMT phenotype. To validate this, we plotted the samples on a two-dimensional plane of epithelial and mesenchymal phenotype scores. Indeed, 600/D1 tumors lie in an intermediate region between the more epithelial 150/D6 and the more mesenchymal 600/D6 tumors (Fig. 2C).
To identify partial EMT gene signatures in our breast microtumor models, we analyzed expression of partial EMT markers in 600/D1 and 600/D6 microtumors using available partial EMT gene signatures from head and neck cancer patients as a reference dataset [26]. We first calculated the enrichment of partial EMT signature using ssGSEA and found a significant increase in the partial EMT signature as early as 600/D1 compared to the 150/D6 tumors (Fig. 2D). We identified 17 partial EMT genes significantly enriched in 600 μm microtumors as early as day 1 and are referred to as ‘600/D1 partial EMT gene signature set’ (Fig. 2E). Over the six-day period in culture, non-migrating 600/D1 microtumors transitioned to collectively migrating phenotype (600/D6). Through comparison of gene expression in 600/D6 versus 150/D6, we identified enrichment of 17 partial EMT genes, referred to as ‘600/D6 partial EMT gene signature set’. The Venn diagram of comparative analysis of ‘600D1 partial EMT gene signature set’ and ‘600D6 partial EMT gene signature set’ identified 10 genes differentially expressed only in 600/D1 and 10 genes differentially expressed only in 600/D6 (Fig. 2E (i)). Seven partial EMT genes were common to both 600D1 and 600D6 microtumors, of which EMP3, HERPUD1, P4HA2, PLOD2 were upregulated and SLC7A8, PSMD2, ACTN1 were downregulated in both 600/D1 and 600/D6 microtumors compared to control 150/D6 microtumors (Fig. 2E (ii)). Of the 10 partial EMT genes differentially expressed only in 600D1 microtumors (Fig. 2E (iii)), NUMB, ITGA5, MAGED1, LGALS1, TNFRSF12A, MXD1, LAMB3, and GPX3 were most upregulated while MPZL1 and MT2A were downregulated (in descending order of expression) compared to 150/D6 microtumors. In ‘600/D6 partial EMT gene signature’, INHBA was the most upregulated gene followed by CLDN7, FRMD6, PSAP and ECM1 while CD99, LTBP1, GRHL2, ARPC1B and THBS1 were top five downregulated genes (in descending order of expression) (Fig. 2E (iv)).

To further understand the expression profile of epithelial marker, E-CAD in our microtumor model, we evaluated surface and total (surface plus intracellular) expression of E-CAD in small (150 μm) and large (600 μm) microtumors. In small non-migratory microtumors, the expression profile of E-CAD did not change from day 1 to day 3 to day 6 (Fig. 2F, top panel). In large microtumors, we observed loss of surface E-CAD over six-day period, which is consistent with our prior work showing higher level of soluble (cleaved surface) E-CAD in the conditioned media of large microtumors [23]. However, analysis of combined surface plus intracellular E-CAD revealed no change in the total E-CAD (Fig. 2F, bottom panel).

3.3. Tumor-intrinsic hypoxia drives partial EMT and collective migration in large microtumors

To identify transcriptional signatures defining collective migration phenotype observed in the large hypoxic microtumors (600/D1, 600/D6) compared to small non-hypoxic microtumors (150/D6), we used the Gene Ontology signatures associated with tissue migration (GO: Tissue Migration) and evaluated the overlap between GO: Tissue Migration in 600/D1 versus 150/D6 and 600/D6 versus 150/D6 comparison groups (Fig. 3A). Compared to 150/D6 microtumors, we identified 18 gene differentially expressed in non-migratory 600/D1 microtumors (denoted as ‘pre-migratory signature’) and 43 genes differentially expressed in collectively migrating 600/D6 microtumors (denoted as ‘migratory gene signature’) (Fig. 3A (i)). Of these differentially expressed genes, 11 genes...
were commonly expressed in both the groups, which maintained their expression over six-day period (Fig. 3A (ii)). Of 18 genes, 7 genes were unique to non-migratory 600/D1 microtumors while out of 43 genes, 32 genes were unique to migratory 600/D6 microtumors (Fig. 3A(iii-iv)). We then calculated the ssGSEA scores for GO: Tissue Migration signatures and found significantly higher ssGSEA scores for the 600/D6 microtumors in comparison to 600/D1 microtumors (Fig. 3B). This was further validated in the two-dimensional plots of Tissue Migration with Hallmark Hypoxia signature as well as with the partial EMT signatures (Fig. 3C and D).

We further analyzed the overlap between hypoxia, partial EMT and tissue migration gene signatures in 600/D1 versus 150/D6 and 600/D6 versus 150/D6 groups to gain mechanistic insights into how tumor-intrinsic hypoxia contributes to partial EMT phenotype, which in turn, can modulate migratory phenotype. As shown in Fig. 3E, only P4HA2 gene was common between early tumor-intrinsic hypoxia and partial EMT gene signature in 600/D1 microtumors. Indeed, P4HA2 is known to be important for hypoxic adaptation and collagen biogenesis [36]. We did not find any overlap between partial EMT and pre-migratory gene signatures in 600/D1 microtumors (Fig. 3E). This analysis supports our observations, wherein 600/D1 microtumors exhibit tumor-intrinsic hypoxia and partial EMT; however, they are yet to migrate. As large microtumors start migrating by day 3, we observed enrichment of both partial EMT and migration gene signatures in 600/D6 microtumors.

This may suggest that tumor-intrinsic hypoxia is responsible for initiating partial EMT and pre-migratory phenotypes, but acquisition of additional changes in the partial EMT genes may be required to further induce collective migration. Further evaluation of the overlap between late tumor-intrinsic hypoxia and 600/D6 partial EMT gene signatures revealed maintenance of P4HA2 as a common gene shared between the two signatures (Fig. 3F). Thus, our analysis points to P4HA2 as a central regulator of tumor-intrinsic hypoxia, partial EMT and migration. Few studies have highlighted role of P4HA2 in driving EMT transition in glioma [37] and tumor migration in prostate cancer [38]; however, whether P4HA2 drives migration through partial EMT states is not yet studied. Comprehensive gene expression analysis of hypoxic, yet non-migratory 600/D1 microtumors as well as that of hypoxic and migratory 600/D6 microtumors suggests that upregulation of P4HA2 expression in response to tumor-intrinsic hypoxia plays a key role in inducing partial EMT states, which can further lead to collective migration. We also identified GRHL2 and THBS1 as common genes between partial EMT and collective migration phenotype in 600/D6 microtumors (Fig. 3F).

To further understand the protein-protein interaction (PPI) between these molecules, we performed STRING pathway analysis [39] (Fig. 3G). No known interaction was found between P4HA2 and GRHL2; however, the PPI network highlighted direct experimental regulation of P4HA2, which exhibit protein-protein interactions with migration related genes namely, THBS1, FN1 and ECM1, that were unique to 600/D6 migratory microtumors.

In addition, we also analyzed the TCGA breast cancer cohort of patients in a subtype specific manner (Luminal A, Luminal B and Basal subtypes) (Fig. 4). In Luminal A subtype of breast cancer, we show that P4HA2 is correlated positively to both CDH1 (an epithelial marker) and SNAI2 (a mesenchymal marker) in patients (Fig. 4A (i-ii)). Furthermore, the sum of the expression of SNAI2 and CDH1, which has been shown to be a characteristic
of partial EMT state [40,41] revealed higher Spearman correlation coefficient with P4HA2 expression than that for the individual correlations of P4HA2 expression with CDH1 and SNAI2 (Fig. 4A (iii)). Finally, the sum of epithelial and mesenchymal ssGSEA scores (a proxy for partial EMT state – both scores being high) of the Luminal A subtype patients are also positively correlated with P4HA2 expression (Fig. 4A (iv)). For Luminal B and Basal subtype of breast cancer, we see similar trends where P4HA2 expression is correlated significantly positively with the sum of epithelial and mesenchymal ssGSEA scores (Fig. 4B and C).

3.4. Inhibition of P4HA2 at early time point attenuates migration in large microtumors

Comparative analysis of common genes among early/late tumor-intrinsic hypoxia, partial EMT and migratory gene signatures (Fig. 3D and E) revealed that hypoxia-responsive P4HA2 gene was upregulated in 600//D1 (Fig. 3D) and its expression was maintained over six-day period in 600//D6 (Fig. 3E). Therefore, we hypothesized that early inhibition of P4HA2 will attenuate collective migration in the large microtumors. To study the effect of P4HA2 inhibition on collective migration, we treated large microtumors with 1,4-DPCA (20 μM), a P4HA inhibitor starting from day 1 to day 6. The photomicrographs of representative microtumors (Fig. 5A) illustrate comparative migratory phenotype in untreated (control) and 1,4-DPCA-treated 600 μm microtumors in a time-dependent manner (D1, D3 and D6). In comparison to untreated microtumors, 1,4-DPCA-treated microtumors showed decrease in the distance of migration travelled by the microtumors from the edge of the well. The quantitative analysis of migrating microtumors post-1,4-DPCA treatment showed reduction in the number of migratory microtumors as early as day 3 (p = 0.0084**), which was sustained over 6 days (p = 0.011*) when compared to untreated microtumors (Fig. 5B).

We also measured the distance of migration in the migratory microtumors treated with 1,4-DPCA in comparison to controls. The distance of migration was significantly reduced in 1,4-DPCA-treated microtumors compared to untreated controls on day 3 (p = 0.001***) and day 6 (p = 0.003**) (Fig. 5C). Quantitative RT-PCR studies showed significant decrease in the expression of both P4HA1 and P4HA2 in 1,4-DPCA treated microtumors compared to controls (Fig. 5D), indicating that 1,4-DPCA is a P4HA inhibitor that is not specific for P4HA2. Together, results from inhibition studies strongly suggest P4HA inhibition as an effective treatment strategy to block collective migration.

4. Discussion

With updated guidelines in the field of EMT, a current focus is to understand the transiently stable partial EMT phenotypes wherein malignant cells acquire mesenchymal characteristics without a complete loss of epithelial markers [1]. Role of tumor microenvironmental factors such as tumor-intrinsic hypoxia, extracellular matrix or stromal factors in inducing or maintaining the partial EMT state remains an important understudied area of research [7]. Tumor-intrinsic hypoxia is one of the key contributors, if not the key driver and has long been known to drive tumor invasion and migration.

We have developed unique microtumor models that recapitulate tumor-intrinsic hypoxia using control over microtumor size. Small 150 μm microtumors remain non-hypoxic and
non-migratory over six-day culture period while large 600 μm microtumors develop hypoxic signatures as early as day 1 [25] and exhibit collective migration starting from day 3 in culture [23]. We have also shown that once acquired, the migratory phenotype is irreversible [22] and that HIF1 inhibition at later time (after day 3) cannot block collective migration [23]. In this report, we exploited these unique microtumor models to investigate the link between tumor-intrinsic hypoxia, partial EMT and collective migration using integrated computational and experimental approaches.

From gene expression analysis, we propose a unique 53 gene-early tumor-intrinsic hypoxia gene signature and 55 gene-late tumor-intrinsic hypoxia gene signature. To the best of our knowledge, this is a first study to identify transcriptional changes in real time in response to naturally induced tumor-intrinsic hypoxia (in contrast to exposure to hypoxic chambers) at different time points as 3D microtumors transition from non-migratory to migratory phenotypes. We found 13 genes differentially expressed only in 600/D1 and 15 genes were expressed only in 600/D6. Of these 13 early tumor-intrinsic hypoxia gene signatures, elevated expression of S100A4 has been correlated to hypoxia-induced tumor invasion and metastasis in oesophageal squamous cell carcinoma and ovarian cancer [42,43]. Other hypoxia-induced genes GYS1 [44,45], FAM162A [46], CCNG2 [47], MT2A [48,49] are known to be induced due to hypoxic response across different cancer types; however, their role as hypoxia responsive genes in breast cancer is not yet reported. Of the 15 late tumor-intrinsic hypoxia gene signatures, PLIN2, JUN and PRKCA are known to be induced in response to hypoxia [50-52].

We also identified transcriptional markers for partial EMT phenotype and propose a unique 17 gene-partial EMT gene signature for non-migratory 600/D1 and 17 gene-partial EMT gene signature for migratory 600/D6 microtumors. The ssGSEA analysis highlights phenotypic plasticity of T47D cells, which exhibit predominantly epithelial phenotype when cultured as non-hypoxic 150 μm microtumors, epithelial-like partial EMT phenotype in hypoxic 600 μm microtumors (day 1) transitioning to more mesenchymal-like partial EMT phenotype on day 6 as hypoxic 600 μm microtumors become migratory. In large microtumors, we also observed loss of surface E-CAD over a six-day period, which is consistent with our prior work showing higher levels of soluble surface E-CAD in the conditioned media of large microtumors [23]. However, analysis of combined surface plus intracellular E-CAD revealed no change in the total E-CAD. Interestingly, similar observations have been reported in pancreatic ductal adenocarcinoma (PDAC) model, highlighting the loss of epithelial phenotype through E-CAD protein internalization instead of transcriptional repression of E-CAD and gain of mesenchymal markers resulting in a partial EMT phenotype [53].

The study further reported that the cells with partial EMT phenotype migrate as clusters, which closely resembles the findings from our 3D breast microtumor model, wherein large microtumors migrate as clusters and exhibit partial EMT phenotype. In a follow-up study using the same PDAC model system, calcium signaling – a key driver of the phenotypic stability factor (PSF), NFATc – was proposed to drive partial EMT [54].

Of note, we also observed differential regulation of some PSFs as early as 600/D1 and also in 600/D6 microtumors. The PSFs stabilize or maintain the partial EMT phenotype
in tumor cells and prevent complete EMT [55]. Recent studies have suggested the role of NUMB endocytic adaptor protein (NUMB), nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor of activated T-cell (NFATc) as phenotypic stability factors [56,57]. Our microarray analysis of 600/D1 and 600/D6 microtumors revealed upregulation of NUMB [56] in hypoxic, but non-migratory 600/D1 microtumors supporting presence of partial EMT as early as day 1. In migratory microtumors (600/D6), GRHL2 was found to be downregulated. While GRHL2 was initially proposed as a PSF [8], more recent studies have indicated that it is more of an MET inducer than a PSF [58-60], thus its downregulation during later time is expected, as cells lose their epithelial traits progressively. In addition to GRHL2, we also identified THBS1, another PSF common between partial EMT and collective migration phenotype in 600/D6 microtumors. THBS1 has been known to drive migration in cancer; however, its role as a partial EMT marker is not yet defined.

Our analysis of overlap between tumor-intrinsic hypoxia, partial EMT and migration signatures suggested P4HA2 as a key link between tumor-intrinsic hypoxia, partial EMT and collective migration. Earlier studies have identified role of HIF-α in inducing P4HA2 expression [61]. In glioma cells, P4HA2 promoted EMT via collagen-dependent PI3K/AKT pathway and P4HA2 knockdown inhibited migration, invasion and EMT [37]. However, whether P4HA2 drives migration through partial EMT states is not yet studied. We identify P4HA2 as a partial EMT marker induced by tumor-intrinsic hypoxia, and demonstrate its role in 3D collective migration through pharmacological inhibition studies. Thus, our study establishes a novel mechanism regulating hypoxia, partial EMT and collective migration.

In breast cancer patient microarray data, high mRNA expression of P4HA2 was associated with collagen deposition (COL1A1, COL3A1 and COL4A1) and poor patient outcomes [62]. Similar findings were reported in DCIS patients (pure versus mixed and invasive carcinoma) and P4HA2 was suggested as an independent predictor of DCIS risk stratification [63]. These studies highlight the clinical relevance of P4HA2 as a drug target in combination with established therapeutics.

5. Conclusion

Taken together, using our unique 3D microtumor models, we show that tumor-intrinsic hypoxia changes transcriptional landscape driving partial EMT and collective migration. We identify P4HA2, known to be important for hypoxic adaptation and collagen biogenesis, as a key regulator of tumor-intrinsic hypoxia, partial EMT and collective migration, which may also serve as potential target to inhibit acquisition of migratory phenotype in breast cancer cells.

Funding

This work was supported by the National Institute of Health (NIH) [R37CA232209] to SS and VSD; the CDMRP BCRP BC210533, the MetaVivor foundation and the Glimmer of Hope foundation (VSD). MKJ was supported by Ramanujan Fellowship awarded by Science and Engineering Research Board (SERB), Department of Science & Technology (DST), Govt. of India (SB/S2/RJN-049/2018) and by InfoSys Foundation, Bangalore.

Aggarwal et al. Page 13

Adv Cancer Biol Metastasis. Author manuscript; available in PMC 2022 October 01.
Abbreviations:

**Abbreviations:**

| Abbreviation | Definition                        |
|--------------|----------------------------------|
| E            | Epithelial                       |
| M            | Mesenchymal                      |
| P4HA2        | Prolyl 4-hydroxylase subunit 2   |
| EMT          | Epithelial-to-mesenchymal transition |
| E-CAD        | E-cadherin                       |
| VIM          | Vimentin                         |
| NCAD         | Neural Cadherin                  |
| TME          | Tumor microenvironment           |
| HIF1a        | Hypoxia inducible factor 1 alpha |
| CTK          | Cytokeratin                      |
| GEO          | Gene Expression Omnibus          |
| GSEA         | Gene Set Enrichment Analysis     |
| MsigDB       | Molecular Signatures Database    |
| ssGSEA       | Single-sample GSEA               |
| TCGA         | The Cancer Genome Atlas          |
| 1,4-DPCA     | 1,4-dihydrophenonthrolin-4-one-3-carboxylic acid |
| P4HA1        | Prolyl 4-hydroxylase subunit 1   |
| NUMB         | NUMB endocytic adaptor protein   |
| ECM1         | Extracellular matrix protein 1   |
| GRHL2        | Grainyhead like transcription factor 2 |
| THBS1        | Thrombospondin 1                 |
| PPI          | Protein-protein interaction      |
| CDH1         | Cadherin 1                       |
| PSF          | Phenotypic stability factor      |
| DCIS         | Ductal carcinoma in situ         |

References

[1]. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, Garcia de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RYJ, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu
[2]. Kalluri R, Weinberg RA, The basics of epithelial-mesenchymal transition, J. Clin. Invest 119 (2009) 1420–1428, 10.1172/JCI39104. [PubMed: 19487818]

[3]. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA, Distinct EMT programs control normal mammary stem cells and tumour-initiating cells, Nature 525 (2015) 256–260, 10.1038/nature14897. [PubMed: 26331542]

[4]. Tian XJ, Zhang H, Xing J, Coupled reversible and irreversible bistable switches underlying TGFbeta-induced epithelial to mesenchymal transition, Biophys. J 105 (2013) 1079–1089, 10.1016/j.bpj.2013.07.011. [PubMed: 23972859]

[5]. Zhang J, Tian XJ, Zhang H, Teng Y, Li R, Bai F, Elankumaran S, Xing J, TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops, Sci. Signal 7 (2014) ra91, 10.1126/scisignal.2005304. [PubMed: 25270257]

[6]. Chaffer CL, San Juan BP, Lim E, Weinberg RA, EMT, cell plasticity and metastasis, Cancer Metastasis Rev. 35 (2016) 645–654, 10.1007/s10555-016-9648-7. [PubMed: 27878502]

[7]. Aggarwal V, Montoya CA, Donnenberg VS, Sant S, Interplay between tumor microenvironment and partial EMT as the driver of tumor progression, iScience 24 (2021), 102113, 10.1016/j.isci.2021.102113. [PubMed: 33659878]

[8]. Jolly MK, Tripathi SC, Jia D, Mooney SM, Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E, Levine H, Stability of the hybrid epithelial/mesenchymal phenotype, Oncotarget 7 (2016) 27067–27084, 10.18632/oncotarget.8166. [PubMed: 27008704]

[9]. Mendez MJ, Hoffman MJ, Cherry EM, Lemmon CA, Weinberg SH, Cell fate forecasting: a data-assimilation approach to predict epithelial-mesenchymal transition, Biophys. J. 118 (2020) 1749–1768, 10.1016/j.bpj.2020.02.011. [PubMed: 32101715]

[10]. Aggarwal V, Miranda O, Johnston PA, Sant S, Three dimensional engineered models to study hypoxia biology in breast cancer, Cancer Lett. 490 (2020) 124–142, 10.1016/j.canlet.2020.05.030. [PubMed: 32569616]

[11]. Baghban R, Roshangar L, Jahanban-Esfahan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P, Tumor microenvironment complexity and therapeutic implications at a glance, Cell Commun. Signal 18 (59) (2020), 10.1186/s12964-020-0530-4.

[12]. Singh M, Venkata Krishnan H, Ranganathan S, Kiesel B, Beumer JH, Sreekumar S, Sant S, Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer, ACS Biomater. Sci. Eng 4 (2018) 421–431, 10.1021/acsbiomaterials.7b00081. [PubMed: 33418733]

[13]. Li Y, Fu L, Li JB, Qin Y, Zeng TT, Zhou J, Zeng ZL, Chen J, Cao TT, Ban X, Qian C, Cai Z, Xie D, Huang P, Guan XY, Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma, Gastroenterology 146 (2014) 1701–1713, 10.1053/j.gastro.2014.02.029, e9. [PubMed: 24561231]

[14]. Sadeghi M, Ordway B, Rafiei I, Borad P, Fang B, Koomen JI, Zhang C, Yoder S, Johnson J, Damaghi M, Integrative analysis of breast cancer cells reveals an epithelial-mesenchymal transition role in adaptation to acidic microenvironment, Front. Oncol 10 (2020) 304, 10.3389/fonc.2020.00304. [PubMed: 32211331]

[15]. Karaozanoglou O, Banerjee S, Sivas H, Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug overexpressing hepatocellular carcinoma cells, Cell. Oncol. (Dordr) 41 (2018) 439–453, 10.1007/s13402-018-0384-6. [PubMed: 29858962]

[16]. Kim SK, Jang SD, Kim H, Chung S, Park JK, Kuh HJ, Phenotypic heterogeneity and plasticity of cancer cell migration in a pancreatic tumor three-dimensional culture model, Cancers (Basel) 12 (2020), 10.3390/cancers12051305.
[17]. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC, Tumor-associated stromal cells as key contributors to the tumor microenvironment, Breast Cancer Res. 18 (2016) 84, 10.1186/s13058-016-0740-2. [PubMed: 27515302]

[18]. Yoshida GJ, Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways, J. Exp. Clin. Cancer Res 39 (2020) 112, 10.1186/s13058-016-0740-2. [PubMed: 27515302]

[19]. Bednarczyk RB, Tuli NY, Hanly EK, Rahoma GB, Maniyyar R, Mittelman A, Geliebter J, Tiwari RK, Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer, Oncotarget 9 (2018) 24272–24282, 10.18632/oncotarget.24917. [PubMed: 29849939]

[20]. Li X, Jolly MK, George JT, Pienta KJ, Levine H, Computational modeling of the crosstalk between macrophage polarization and tumor cell plasticity in the tumor microenvironment, Front. Oncol 9 (2019) 10, 10.3389/onc.2019.00010. [PubMed: 30729096]

[21]. Singh M, Close DA, Mukundan S, Johnston PA, Sant S, Production of uniform 3D microtumors in hydrogel microwell Arrays for measurement of viability, morphology, and signaling pathway activation, Assay Drug Dev. Technol 13 (2015) 570–583, 10.1089/adt.2015.662. [PubMed: 26274587]

[22]. Singh M, Mukundan S, Jaramillo M, Oesterreich S, Sant S, Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression, Cancer Res. 76 (2016) 3732–3743, 10.1158/0008-5472.CAN-15-2304. [PubMed: 27216179]

[23]. Singh M, Tian XJ, Donnenberg VS, Watson AM, Zhang J, Stabile LP, Watkins SC, Xing J, Sant S, Targeting the temporal dynamics of hypoxia-induced tumor-secreted factors halts tumor migration, Cancer Res. 79 (2019) 2962–2977, 10.1158/0008-5472.CAN-18-3151. [PubMed: 30952634]

[24]. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, Basse P, Brufsky AM, Localization of CD44 and CD90 positive cells to the invasive front of breast tumors, Cytometry B Clin. Cytometry 78 (2010) 287–301, 10.1002/cyto.b.20530. [PubMed: 20533389]

[25]. Ardila DC, Aggarwal V, Singh M, Chattopadhyay A, Chaparala S, Sant S, Identifying molecular signatures of distinct modes of collective migration in response to the microenvironment using three-dimensional breast cancer models, Cancers (Basel) 13 (2021), 10.3390/cancers13061429.

[26]. Puram SV, Tirosch I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, Deschler DG, Varvares MA, Mylvaganam R, Rozenblatt-Rosen O, Rocco JW, Faquin WC, Lin DT, Regev A, Bernstein BE, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer, Cell 171 (2017) 1611–1624 e24, 10.1016/j.cell.2017.10.044. [PubMed: 29198524]

[27]. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, Ami GOH, Web G, Presence Working, AmiGO: online access to ontology and annotation data, Bioinformatics 25 (2009) 288–289, 10.1093/bioinformatics/btn615. [PubMed: 19033274]

[28]. Mi H, Muruganujan A, Ebert BL, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A 102 (2005) 15545–15550, 10.1073/pnas.0506580102. [PubMed: 16199517]

[29]. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A 102 (2005) 15545–15550, 10.1073/pnas.0506580102. [PubMed: 16199517]

[30]. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Merrel C, Silver SI, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature 462 (2009) 108–112, 10.1038/nature08460. [PubMed: 19847166]

[31]. Donnenberg VS, Landreneau RJ, Donnenberg AD, Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents, J. Contr. Release 122 (2007) 385–391, 10.1016/j.conrel.2007.05.005.
[32]. Cossarizza A, Chang H-D, Radbruch A, Akdis M, André I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Becro C, Blanco A, Borsellino G, Boulaïs PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavana A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellacona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Ensor C, Everts B, Dreher A, Falk PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Ghibelli L, Goettlinger C, Goodyear CS, Gori A, Gross MG, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kühn N, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lukic P, Maueröder C, McGrath M, McNees I, Mei HE, Melchers F, Melzer S, Mielzen D, Mills K, Mirre D, Mjöberg J, Moore J, Morgan B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O’Connor G, Ouyang W, Oxiuia A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRD, Rajwa B, Rehmann JA, Recktenwald D, Remmerswaal EB, Revzani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Scheffold A, Schiemann M, Schmid EG, Schimsky E, Schmid SA, Schoder K, Schüller T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon A-K, Spidlen J, Stall AM, Stange P, Stahl AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tordiglione J, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Voll H-D, von Volkmann K, Waisman M, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiestermann A, Wijers J, Williamsky G, Wing J, Wist P, Wu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J, Guidelines for the use of flow cytometry and cell sorting in immunological studies, Eur. J. Immunol 47 (2017) 1584–1797, 10.1002/eji.201646632. [PubMed: 29023707]

[33]. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP, Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients, EMBO Mol. Med 6 (2014) 1279–1293, 10.15252/emmm.201404208. [PubMed: 25214461]

[34]. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A, Fiji: an open-source platform for biological-image analysis, Nat. Methods 9 (2012) 676–682, 10.1038/nmeth.22743772

[35]. Livak KJ, Schmitgen TD, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods 25 (2001) 402–408, 10.1006/meth.2001.1262. [PubMed: 11846609]

[36]. Myllyharju J, Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis, Matrix Biol. 22 (2003) 15–24, 10.1016/s0945-053x(03)00006-4. [PubMed: 12714038]

[37]. Lin J, Jiang L, Wang X, Wei W, Song C, Cui Y, Wu X, Qiu G, P4HA2 promotes epithelial-to-mesenchymal transition and glioma malignancy through the collagen-dependent PI3K/AKT pathway, JAMA Oncol. 2021 (2021), 1406853, 10.1155/2021/1406853. [PubMed: 34471235]

[38]. Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P, Song HJ, Mak CSL, Park J, Zheng SE, Huang A, Ma X, Chen R, Chang Q, Logothetis CJ, Jain AK, Lin SH, Katayama H, Hanash S, Wang G, P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis, Oncogene 40 (2021) 6049–6056, 10.1038/s41388-021-02000-3. [PubMed: 34471235]

[39]. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, Jensen LJ, von Mering C, The STRING database in 2021: customizable
protein-protein networks, and functional characterization of user-uploaded gene/measurement sets, Nucleic Acids Res. 49 (2021) D605–D612, 10.1093/nar/gkaa1074. [PubMed: 33237311]

[40]. Sterneck E, Poria DK, Balamurugan K, Slug, E-Cadherin, Stealth accomplices? Front. Mol. Biosci 7 (2020) 138, 10.3389/fmolb.2020.00138. [PubMed: 32760736]

[41]. Subbalakshmi AR, Sahoo S, Biswas K, Jolly MK, A computational systems biology approach identifies SLUG as a mediator of partial epithelial-mesenchymal transition (EMT), Cells Tissues Organs (2021) 1–14, 10.1159/000512520.

[42]. Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T, Konishi I, Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1alpha to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene, Int. J. Cancer 131 (2012) 1755–1767, 10.1002/ijc.27448. [PubMed: 22287060]

[43]. Xuan X, Li Q, Zhang Z, Du Y, Liu P, Increased expression levels of S100A4 associated with hypoxia-induced invasion and metastasis in esophageal squamous cell cancer, Tumour Biol 35 (2014) 12535–12543, 10.1007/s13277-014-2573-x. [PubMed: 25217321]

[44]. Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T, Ohkawa K, Hypoxia promotes glycoegen synthesis and accumulation in human ovarian clear cell carcinoma, Int. J. Oncol 40 (2012) 2122–2130, 10.3892/ijo.2012.1406. [PubMed: 22447231]

[45]. Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-Barahona A, Vazquez S, Ordonez A, Cuevas Y, Saez-Morales D, Garcia-Bermejo ML, Landazuri MO, Guinovart J, del Peso L, Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1, PLoS One 5 (2010), e9644, 10.1371/journal.pone.0009644. [PubMed: 20300197]

[46]. Lee MJ, Kim JY, Suk K, Park JH, Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway, Mol. Cell Biol 24 (2004) 3918–3927, 10.1007/s13277-014-2573-x. [PubMed: 15082785]

[47]. Ratushnyy AY, Rudimova YV, Buravkova LB, Alteration of hypoxia-associated gene expression in replicatively senescent mesenchymal stromal cells under physiological oxygen level, Biochemistry (Mosc.) 84 (2019) 263–271, 10.1134/S0006297919030088. [PubMed: 31221064]

[48]. Dube A, Harrisson JF, Saint-Gelais G, Seguin C, Hypoxia acts through multiple signaling pathways to induce metallothionein transactivation by the metal-responsive transcription factor-1 (MTF-1), Biochem. Cell. Biol 89 (2011) 562–577, 10.1139/o11-063. [PubMed: 22087877]

[49]. Yamasaki M, Nomura T, Sato F, Mimata H, Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells, Oncol. Rep 18 (2007) 1145–1153, 10.3892/or.18.5.1145. [PubMed: 17914565]

[50]. Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, Bobrovnikova-Marjon E, Diehl JA, Keith B, Simon MC, HIF2alpha-Dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma, Cancer Discov. 5 (2015) 652–667, 10.1158/2159-8290.CD-14-1507. [PubMed: 25829424]

[51]. Salnikow K, Kluz T, Costa M, Figueiral D, Demidenko ZN, Xie K, Blagosklonny MV, The regulation of hypoxia genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia, Mol. Cell Biol 22 (2002) 1734–1741, 10.1128/MCB.22.6.1734-1741.2002. [PubMed: 11865053]

[52]. Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J, Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma, Comput. Struct. Biotechnol. J19 (2021) 2775–2789, 10.1016/j.csbj.2021.03.033. [PubMed: 34093992]

[53]. Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, Bar-Sagi D, Stanger BZ, EMT subtype influences epithelial plasticity and mode of cell migration, Dev. Cell 45 (2018) 681–695, 10.1016/j.devcel.2018.05.027, e4. [PubMed: 29920274]

[54]. Norgard RJ, Piturressi JR, Maddipati R, Aiello-Couzo NM, Balli D, Li J, Yamazoe T, Wengyn MD, Millstein ID, Folkert IW, Rosario-Berrios DN, Kim IK, Bassett JB, Payne R, Berry CT, Feng X, Sun K, Cioffi M, Chakraborty P, Jolly MK, Gutkind JS, Lyden D, Freedman BD, Foskett JK, Rustgi AK, Stanger BZ, Calcium signaling induces a partial EMT, EMBO Rep. 22 (2021), e51872, 10.15252/embr.202051872. [PubMed: 34324787]
[55]. Yaswen P, Reinforcing targeted therapeutics with phenotypic stability factors, Cell Cycle 13 (2014) 3818–3822, 10.4161/15384101.2014.985071. [PubMed: 25483053]

[56]. Bocci F, Jolly MK, Tripathi SC, Aguilar M, Hanash SM, Levine H, Onuchic JN, Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling, J. R. Soc. Interface 14 (2017), 10.1098/rsif.2017.0512.

[57]. Subbalakshmi AR, Kundnani D, Biswas K, Ghosh A, Hanash SM, Tripathi SC, Jolly MK, NFATc acts as a non-canonical phenotypic stability factor for a hybrid epithelial/mesenchymal phenotype, Front. Oncol 10 (2020), 553342, 10.3389/fonc.2020.553342. [PubMed: 33014880]

[58]. Chung VY, Tan TZ, Tan M, Wong MK, Kuay KT, Yang Z, Ye J, Muller J, Koh CM, Guccione E, Thiery JP, Huang RY, GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification, Sci. Rep 6 (2016), 19943, 10.1038/srep19943. [PubMed: 26887977]

[59]. Chung VY, Tan TZ, Ye J, Huang RL, Lai HC, Kappei D, Wollmann H, Guccione E, Huang RY, The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells, Commun Biol. 2 (2019) 272, 10.1038/s42003-019-0506-3. [PubMed: 31372511]

[60]. Jia W, Tripathi S, Chakraborty P, Chedere A, Rangarajan A, Levine H, Jolly MK, Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT, Oncotarget 11 (2020) 2611–2624, 10.18632/oncotarget.27651. [PubMed: 32676163]

[61]. Jung HY, Fattet L, Yang J, Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis, Clin. Cancer Res 21 (2015) 962–968, 10.1158/1078-0432.CCR-13-3173. [PubMed: 25107915]

[62]. Xiong G, Deng L, Zhu J, Rychahou PG, Xu R, Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition, BMC Cancer 14 (1) (2014), 10.1186/1471-2407-14-1.

[63]. Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA, Prolyl-4-hydroxylase Alpha subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS), Br. J. Cancer 119 (2018) 1518–1526, 10.1038/s41416-018-0337-x. [PubMed: 30410060]
Fig. 1. Tumor-intrinsic hypoxia is highly enriched in large microtumors.

(A) Principal component analysis (PCA) plot for similarity assessment of gene expression levels across biological replicates of 150/D6, 600/D1 and 600/D6 microtumors fabricated from T47D cells; (B) ssGSEA enrichment of key biological processes in 600/D1 versus 150/D6 and 600/D6 versus 150/D6 comparison groups. Hallmark Hypoxia is enriched as early as day 1 and maintained over six-day period. Only hallmark gene sets, which show significant differences have been shown (p-value < 0.05; Student’s T-test); (C) Comparison of ssGSEA score analysis for Hallmark Hypoxia in 600/D1 and 600/D6 groups individually with 150/D6 microtumors as control shows significant enrichment of tumor-intrinsic hypoxia in both 600/D1 and 600/D6 groups. (D) (i) Venn diagram comparison of Hallmark Hypoxia with 600/D1 versus 150/D6 and 600/D6 versus 150/D6 comparison groups shows an overlap of 53 genes for 600/D1 (denoted as early tumor-intrinsic hypoxia gene signature) and 55 genes for 600/D6 (denoted as late tumor-intrinsic hypoxia gene signature), (ii) Forty genes are common among Hallmark Hypoxia, early and late tumor-intrinsic hypoxia gene signatures. (iii) Thirteen genes are differentially expressed only in 600/D1 versus 150/D6 and (iv) 15 genes are differentially expressed only in 600/D6 versus 150/D6. These are represented as heat maps with corresponding intensity values of genes from biological replicates in 600/D1 and 600/D6 versus 150/D6 group. In the heatmaps, ‘red’ represents upregulated status and ‘blue’ represents downregulated status. The corresponding gene names are illustrated in ‘red’ for upregulated status and ‘green’ for downregulated status.
Fig. 2. Large microtumors exhibit enrichment of partial EMT signature in comparison to small microtumors.

(A) ssGSEA score analysis for ‘Epithelial signature’ in 600/D1 and 600/D6 groups individually with 150/D6 microtumors as control shows significant decrease in epithelial signature over six-day period in both 600/D1 (p = 0.01*) and 600/D6 (p = 0.01*) microtumors; (B) Comparison of ssGSEA score analysis for ‘Mesenchymal signature’ in 600/D1 and 600/D6 groups individually with 150/D6 microtumors as control shows significant increase in expression of mesenchymal signatures over six-day period in 600/D6 (p = 0.01*) group but not in the 600/D1 group; (C) 2D plots showing Epithelial-Mesenchymal characteristics of 150/D6, 600/D1 and 600/D6 microtumors. (D) Comparison of ssGSEA score analysis for ‘partial EMT signature’ in 600/D1 and 600/D6 groups individually with 150/D6 microtumors as control shows significant increase in expression of partial EMT signatures [26] as early as day 1 in 600/D1 microtumors (p = 0.01*) and is maintained over six-day period in 600/D6 (p = 0.01*); (E) (i) Venn diagram comparison of partial EMT signature set [26] with 600/D1 versus 150/D6 and 600/D6 versus 150/D6 group shows that total 17 genes are enriched in 600/D1 versus 150/D6 as well as in 600/D6 versus 150/D6 group with an overlap of 7 genes in both these groups. Heatmap shows the intensity values of genes from biological replicates in 600/D1, 600/D6 and 150/D6 group as separate list for (ii) 7 genes common to both the groups, (iii) 10 differentially regulated genes present only in 600/D1 versus 150/D6 and (iv) 10 genes present only in 600/D6 versus 150/D6. In the heatmap, ‘red’ represents upregulated status and ‘blue’ represents downregulated status. The corresponding gene names are illustrated with ‘red’ for upregulated status and ‘green’ for downregulated status; (F) Time-dependent expression of E-cadherin (E-CAD: surface ECAD and total ECAD) and intracellular pan-cytokeratin (iCTK) in T47D cells in 150 μm and 600 μm microtumors over day 1, 3 and 6.
Fig. 3. Tumor-intrinsic hypoxia drives partial EMT and collective migration in large microtumors.

(A) (i) Venn diagram comparison of GO: Tissue Migration with 600/D1 versus 150D6 and 600D6 versus 150D6 comparison groups shows an overlap of 18 genes with 600/D1 (denoted as pre-migratory gene signature) and 43 genes with 600/D6 (denoted as migratory gene signature). (ii) Eleven genes are common among GO: Tissue Migration, pre-migratory and migratory gene signatures. (iii) Seven genes are differentially expressed only in 600/D1 versus 150/D6 and (iv) 32 genes are differentially expressed only in 600/D6 versus 150/D6. These are represented as heat maps with corresponding intensity values of genes from biological replicates in 600/D1 and 600/D6 versus 150/D6 group. In the heatmaps, ‘red’ represents upregulated status and ‘blue’ represents downregulated status. The corresponding gene names are illustrated in ‘red’ for upregulated status and ‘green’ for downregulated status. (B) Comparison of ssGSEA score analysis for GO Tissue Migration in 600/D1 and 600/D6 microtumors with 150/D6 microtumors as control shows significant increase in tissue migration only in 600/D6 (p = 0.005*) microtumors, but not in the 600/D1 microtumors; (C) 2D plot of Hallmark Hypoxia and GO: Tissue Migration showing the trajectory of transition of the microtumors on the phenotypic space of hypoxia and tissue migration; (D) 2D plot of partial EMT signature and GO:Tissue Migration showing the trajectory of transition of the microtumors on the phenotypic space of partial EMT and tissue migration; (E) Venn diagram comparison of early tumor-intrinsic hypoxia, partial EMT and pre-migratory gene signature set in 600/D1 versus 150/D6 shows an overlap of one gene signature (P4HA2) between tumor-intrinsic hypoxia and partial EMT. Heatmap shows the intensity values of P4HA2 from biological replicates in 600/D1 and 150/D6. The corresponding gene names are illustrated with ‘red’ for upregulated status. (F) Venn diagram comparison of late tumor-intrinsic hypoxia, partial EMT and migratory gene signature set in 600/D6 versus 150/D6 shows an overlap of one gene signature (P4HA2) between tumor-
intrinsic hypoxia and partial EMT, and two genes (**GRHL2, THBS1**) between partial EMT and migratory gene signature. Heatmap shows the intensity values of genes from biological replicates in 600/D6 and 150/D6 group. In the heatmaps, ‘red’ represents upregulated status and ‘blue’ represents downregulated status. The corresponding gene names are illustrated with ‘red’ for upregulated status and ‘green’ for downregulated status. (G) Protein-protein interaction (PPI) network analysis of gene signatures common among hypoxia, partial EMT and tissue migration i.e. **P4HA2, GRHL2, THBS1**.
Fig. 4. Gene expression analysis of P4HA2 with Epithelial and Mesenchymal genes in the TCGA cohort of breast cancer patients.

(A (i-iv)) Scatterplots showing the correlations of P4HA2 with CDH1 (epithelial marker), SNAI2 (mesenchymal marker), CDH1+SNAI2 (a proxy for partial EMT phenotype) and sum of ssGSEA scores of Epithelial and Mesenchymal gene sets (a proxy for partial EMT phenotype) in the Luminal A subtype of breast cancer patients. Scatterplots showing the correlations of P4HA2 with and sum of ssGSEA scores of Epithelial and Mesenchymal gene sets (a proxy for partial EMT phenotype) in the (B) Luminal B and (C) Basal subtype of breast cancer patients. Spearman correlation coefficients and the corresponding p-values are indicated for each scatterplot.
Fig. 5. Inhibition of P4HA2 at early time point attenuates migration in large microtumors.

(A) Photomicrographs of migrating 600 μm microtumors in control (top panel) and 1,4-DPCA-treated (bottom panel) devices over day 1, day 3 and day 6; (B) Percentage migrating microtumors on 600/D3 and 600/D6 in control and 1,4-DPCA treated 600 μm microtumors; (C) Effect of 1,4-DPCA on distance of migration travelled by 600 μm microtumors evaluated on day 3 and day 6 for 10 individual tumors. 1,4-DPCA significantly reduced distance of migration on day 3 and day 6 as compared to the untreated microtumors; (D) Effect of 1,4-DPCA inhibition on the expression of P4HA2 in treated 600 μm microtumors. Fold change (mRNA expression) for P4HA1 and P4HA2 was determined by quantitative real-time PCR for microtumors harvested on day 6 in untreated and 1,4-DPCA treated 600/D6 microtumors. GAPDH, the housekeeping gene was used as a reference gene. Relative expression of P4HA1 and P4HA2 was compared to untreated 600/D6 controls (dotted line parallel to x-axis on bar graph). P4HA1 and P4HA2 expression decreased significantly in 1,4-DPCA treated 600 μm microtumors. Data is represented as mean ± SEM (Unpaired t-test, *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated 600/D6).